What compounded semaglutide is, and where it stands in 2026

Compounded semaglutide uses the same named drug as Ozempic and Wegovy, but it is a different preparation from the FDA-approved products. The agency says plainly that it “does not review compounded drugs for safety, effectiveness or quality before they are marketed” ^[2]. That is a premarket-review distinction, not a claim that compounding pharmacies face no oversight. The exact preparation, concentration, dispensing pharmacy and quality documentation matter.

It copies the molecule, not the product

Compounded semaglutide shares a named active ingredient with Ozempic and Wegovy. Formulation, concentration, container, additional ingredients and testing can differ. The approved product’s clinical record does not establish the performance of every pharmacy preparation.

Two compounding frameworks matter here. A 503A pharmacy is a state-licensed pharmacy that compounds for a named patient’s prescription. An FDA-registered 503B outsourcing facility may compound without individual prescriptions, subject to its own requirements. When it uses a bulk drug substance, the shortage-list or 503B clinical-need list requirements matter ^[3]. This is not a complete description of every possible manufacturing or compounding pathway.

Brand semaglutide is a different story. FDA approved Ozempic for type 2 diabetes in December 2017 ^[8] and Wegovy for weight management in June 2021 ^[9]. Wegovy’s adult cardiovascular indication requires established cardiovascular disease and obesity or overweight. Its MASH indication is injection-only in adults with noncirrhotic disease and F2–F3 fibrosis, under accelerated approval ^[6].

The last row matters more than it looks. FDA has warned companies that sold semaglutide “falsely labeled ‘for research purposes’ or ‘not for human consumption,’” often with dosing instructions attached ^[2]. Those warnings concern products marketed for human use despite research-only labels. They do not declare all legitimate laboratory research unlawful.

Where the semaglutide itself comes from

The raw drug ingredient is called the active pharmaceutical ingredient, or API. A brand name on a comparison page does not establish the compounder’s supplier, ingredient identity or quality. Ask the pharmacy which API source it uses and what incoming-material and finished-preparation testing it performs.

FDA has set up a “green list” import alert (66-80) to stop GLP-1 ingredients with “potential quality concerns” at the border ^[2]. The alert exempts API manufacturers that, based on an FDA inspection or other evaluation, appear compliant with the agency’s standards. So a pharmacy can still source lawfully, but the supplier is not established by the medicine’s name alone. That’s one more question for your program: which pharmacy, and does it test each shipment it receives?

What’s in the vial depends on the pharmacy

Two compounded semaglutide products can differ in salt form, added vitamins, concentration and beyond-use date. So no, all compounded semaglutide is not the same.

Salt form. Approved semaglutide is the base molecule. Some compounders have used semaglutide sodium or semaglutide acetate instead. FDA says these “are different active ingredients than are used in the approved drugs” and that it is “not aware of any lawful basis for their use in compounding” ^[2]. If your pharmacy label names sodium or acetate, ask your prescriber about it before the next refill.

Add-ins. Many programs sell semaglutide mixed with vitamin B12, B6 or glycine. Adding a vitamin doesn’t automatically make a product a different drug in FDA’s eyes. FDA’s own example: a semaglutide and B12 injection may still count as “essentially a copy” of the brand when the route matches and the amounts are “within 10% of the strengths of the respective commercially available drug products” ^[1]. How much B12 is in a given vial varies by pharmacy. Ask for the dispensing label and written formulation details; do not infer the amount from an online name.

In an August–October 2025 secret-shopper study of 75 clinics and med spas in West Virginia and Oklahoma, 56.0% offered GLP-1 products combined with B vitamins ^[16]. The study identified 23 supplier facilities and reported that 4 of 21 checked lacked sterile-compounding licenses in its assessment. These are findings from selected businesses in two states, not a national prevalence estimate or an independent current license check for your pharmacy.

Impurities. A 2026 lab study found different impurity profiles in compounded semaglutide than in the originator product, and larger gaps in strength after light exposure ^[17]. Novo Nordisk funded the study; the authors were employees/shareholders or, for one shareholder, an employee when the study was conducted, and the work was done in cell and chemistry assays, not in patients. Treat it as a reason to ask questions, not as proof of harm.

Why it became so common: the 2022–2025 shortage

Compounded semaglutide spread because semaglutide injection sat on FDA’s shortage list from 2022 until February 21, 2025 ^[1]. Shortage status affects particular essentially-copy restrictions, while other statutory conditions still apply. When FDA declared the shortage resolved, it gave 503A pharmacies until April 22, 2025 and 503B facilities until May 22, 2025 to wind down.

Where it stands legally today: narrow, patient-specific, not routine

An identified patient’s prescription is one element of the section 503A framework. Its essentially-copy restriction concerns making copies of the brand “regularly or in inordinate amounts.” For the essentially-copy restriction, FDA describes enforcement discretion involving four or fewer prescriptions of a compounded drug product in a calendar month. That is not blanket permission to disregard other legal conditions ^[1].

A separate significant-difference provision concerns cases when “a prescriber determines and documents the compounded drug product contains a change that produces a significant difference from the commercially available drug product for an identified individual patient” ^[1]. A promotional word such as personalized does not establish that the provision applies; a prescription and documented significant difference must be assessed with the other requirements.

Outsourcing facilities face a tighter wall. FDA’s April 2026 reminder says semaglutide does “not currently appear on the 503B bulks list or on FDA’s drug shortage list” ^[1]. In April 2026 FDA proposed excluding it from that list, “finding no clinical need” for outsourcing facilities to compound it from bulk ^[3]. The comment period ran to July 30, 2026 ^[5]. For what a final decision would change, see whether compounded semaglutide will be banned.

What branded trials can establish about a compounded preparation

The STEP 1 trial below tested a specified branded formulation. It did not test every pharmacy’s compounded semaglutide preparation or establish equivalence for a product sold online. In STEP 1, 1,961 adults without diabetes lost 14.9% of body weight on 2.4 mg weekly over 68 weeks, against 2.4% on placebo ^[12].

A shared ingredient name, dose claim or laboratory certificate alone does not establish clinical equivalence. Ask for evidence specific to the proposed preparation; the branded results cannot become a guaranteed pharmacy-product result. More on the evidence and its limits is in does compounded semaglutide work.

What FDA has flagged on safety

FDA’s concerns are specific: dosing errors with multi-dose vials, salt forms, fraudulent labels, warm shipments and a growing count of adverse-event reports. As of May 31, 2026, FDA had received 990 reports associated with compounded semaglutide, and it says such events are likely underreported. Reports do not establish causality, incidence or comparative risk ^[2].

• Dosing errors. FDA has received reports, “some requiring hospitalization,” that may be linked to dosing errors with compounded injectable semaglutide ^[2].
• Vials past 28 days. FDA recommends multidose vials of sterile medicine be used within 28 days of first use, even if the compounder’s label says longer. An earlier beyond-use date, expiry, storage failure or suspected contamination may require earlier disposal ^[2].
• Warm deliveries. FDA recommends not using any injectable GLP-1 that “arrives warm or with insufficient refrigeration” ^[2].
• Fake pharmacies. FDA has seen labels naming pharmacies that don’t exist, or that didn’t make the product ^[2].

The brand labels also carry a boxed warning. Semaglutide caused thyroid C-cell tumors in rodents, and it isn’t known whether it does in people; it’s not for anyone with a personal or family history of medullary thyroid cancer or MEN 2 ^[6]. Serious allergy to semaglutide or the exact product’s ingredients is also a contraindication in the approved labels. A clinician should discuss relevant semaglutide risks rather than assuming a pharmacy-made preparation avoids them; the brand’s rates are not a direct measurement of the compound.

The brand label provides important context, but its incidence figures are not measurements of a compounded product. Examples in the labeled trial populations include nausea, diarrhea, vomiting, constipation, stomach pain, headache, tiredness, indigestion, dizziness, bloating, burping, gas, reflux and hair loss ^[6]. In STEP 1, 4.5% stopped treatment because of stomach side effects, against 0.8% on placebo ^[12]. The label also warns about pancreatitis, gallbladder problems and kidney injury from dehydration. Those rates come from the brand at labeled doses; they cannot be transferred directly to a compounded formulation or used to infer that product’s comparative risk. The full safety picture, side effects included, is in is compounded semaglutide safe. Storage questions are covered in keeping compounded semaglutide in the fridge.

Forms you’ll see: injections, drops, lozenges and tablets

Programs advertise injectable semaglutide preparations, including multidose vials. Some programs also sell sublingual drops, lozenges, dissolving tablets or capsules. A pharmacy’s sublingual or dissolving preparation is not the approved swallowed Wegovy, Rybelsus or Ozempic tablet. The branded tablet trials do not establish absorption or effectiveness of that exact compounded formulation.

That’s a real gap. Novo Nordisk’s approved semaglutide tablets rely on an absorption enhancer called SNAC and a strict morning fasting routine, and even then only about 1% to 2% of the dose is absorbed ^[6]. That percentage concerns the cited Wegovy tablet; original Rybelsus has a different estimated bioavailability. It does not establish how a compounded drop or lozenge behaves. The approved pills are explained in oral semaglutide.

What compounded semaglutide costs right now

Across 25 online programs, compounded semaglutide injections run $75–$349 a month as of this update, among the current comparable price records. The quoted range is a publisher comparison, not a promise that every product or plan is suitable, available or compliant. Watch for prepaid packages and four-week billing, which change what a year costs.

Compare the exact dose, required clinical fees, quoted supply and charge interval. A supply lasting four weeks does not by itself prove a recurring 28-day charge. If payment occurs at enrollment and every 28 days, 14 payment dates fall within the first 365 days; the final payment covers time beyond that year. Annualizing a recurring rate is a different calculation. Prepaid offers also need a written covered term and refund rule. Ask what happens to unused prepaid value if treatment changes.

The Collective review, Brightmeds review and Found review explain different care and billing structures without making them clinically interchangeable. Use the cost calculator with a written quote. A monthly comparison should distinguish a recurring charge from a shorter supply and an introductory figure from a continuing offer.

Compare eligible branded offers using their actual supply units. NovoCare’s self-pay offer lists Wegovy pens at $199 a month for the first two fills for new patients at the two lowest doses, through December 31, 2026, then $349 per offer-defined month of four pens ^[10]. The Wegovy pill starts at $149 per 30 tablets at 1.5 mg; the 25 mg maintenance strength is $299. Offer eligibility, expiration and separate clinical fees matter. The full cost breakdown, including what changes the price, is in how much compounded semaglutide costs. Programs side by side are on the compounded semaglutide providers scorecard.

Compounded semaglutide vs compounded tirzepatide: different molecules

Tirzepatide is a different drug that acts on two hormone receptors (GIP and GLP-1) instead of one. Head to head, the brand versions weren’t close: in SURMOUNT-5, people on tirzepatide lost 20.2% of their weight at 72 weeks, against 13.7% on semaglutide ^[15]. That trial used Zepbound and Wegovy, not compounded products. The compounded version is covered in compounded tirzepatide explained, and the brand drugs are compared in semaglutide vs tirzepatide.

The long-run question: what happens when you stop

The exploratory STEP 1 extension followed 327 selected participants after both semaglutide and lifestyle intervention stopped at week 68. The semaglutide subgroup regained 11.6 percentage points of 17.3 previously lost, remaining 5.6% below baseline; most cardiometabolic variables moved toward baseline ^[13]. That is branded-formulation evidence from a selected subgroup, not proof of a compounded preparation’s long-term result or an individual prediction.

A longer-term budget should allow for clinical reassessment, changed treatment and possible access or price changes. A product that’s cheap now but legally uncertain carries a second cost: the chance that you’ll need to switch mid-course. If your goal is metabolic health for the next decade, not just this year, plan for both. SELECT assessed first cardiovascular events over mean 39.8-month follow-up; that is not a fixed waiting period before anyone can benefit ^[14].

Questions to ask a prescriber before you start

1. Which pharmacy will fill my prescription, and is it licensed in my state?
2. Is the ingredient semaglutide base, or a salt form such as sodium or acetate?
3. What else is in the vial, and at what strength?
4. What documented reason makes this compounded product right for me instead of Wegovy or Ozempic?
5. Who answers my questions after the medicine arrives, and how fast?
6. If the rules change, what’s the plan to move me to a brand product?

How to tell if your semaglutide is compounded

Authentic brand semaglutide comes in specified Novo Nordisk pens, syringes or tablet packaging with the Ozempic, Wegovy or Rybelsus name on it ^{[6] [7]}. Compounded products may use pharmacy-labeled vials or other containers. Packaging is a clue, not proof: confirm authenticity and preparation details directly with the dispensing pharmacy.

• Authentic manufacturer packaging helps identify a branded product, but a brand name alone does not prove authenticity; FDA also warns about counterfeit Ozempic.
• A pharmacy-labeled preparation or an added ingredient can indicate compounding, but confirm the exact product and its source.
• No pharmacy name, a misspelled label or an address you can’t find is one of FDA’s red flags ^[2].

You can check a pharmacy’s license with your state board of pharmacy. FDA’s BeSafeRx page explains how to spot an online pharmacy that isn’t licensed ^[11]. The difference from the brand product in detail is in compounded semaglutide vs Ozempic.

How to get it, and the brand routes that now compete

Compounded semaglutide needs a prescription from a licensed clinician, after a clinical assessment; telehealth is one route. A platform may describe pharmacy partners or available forms, but that does not establish which pharmacy will actually dispense to you, its current license or the preparation’s legal basis. Ask any program which pharmacy fills your order before you pay.

Step-by-step access, from intake to delivery, is in how to get compounded semaglutide. If you’re weighing a smaller dose for other goals, read microdosing GLP-1s first; small-dose marketing does not establish a safe or effective regimen for the proposed goal.